Human papillomavirus (HPV) infection acquisition is a necessary step in the development of cervical cancer. No study has systematically quantified the rate of newly acquired HPV infections from the published literature and determined its relationship with age. We performed a systematic review and meta-analysis to describe incident HPV infections in women. Medline® and Thomson Reuters Web of Science via PubMed® databases were searched. A total of 46 of 5136 studies met inclusion criteria and contributed results. We conducted a meta-regression analysis of 13 studies, which reported incidence rate estimates on over 13 high-risk HPV types, to provide pooled stratum-specific incidence rates and rate ratios for key population and study characteristics among 8488 women. Studies with mean age < 30 years had relatively higher HPV incidence rates compared to studies with mean age ≥30 years: relative risk = 3.12; 95% CI: 1.41–6.93. HPV-16 was most frequently detected, followed by HPV-18: relative risk = 0.47; 95% CI: 0.33–0.67, and by HPV-58: relative risk = 0.45; 95% CI: 0.27–0.74. Younger age is a key predictor of genital HPV incidence in women. These data on the relative distribution of incident HPV infections will provide a baseline comparison for monitoring of changes in HPV incidence following the implementation of population-level HPV vaccination.
WalboomersJMJacobsMVManosMM, et al.
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol1999;
189: 12–19.
2.
MunozNCastellsagueXde GonzalezAB, et al.
Chapter 1: HPV in the etiology of human cancer. Vaccine2006;
24: S3/1–10.
3.
FerlayJSIErvikMDikshitR, et al.GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer, 2013.
4.
VillaLLCostaRLPettaCA, et al.
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer2006;
95: 1459–1466.
5.
HarperDMFrancoELWheelerCM, et al.
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet2006;
367: 1247–1255.
6.
LehtinenMPaavonenJWheelerCM, et al.
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol2012;
13: 89–99.
7.
WheelerCMCastellsaguéXGarlandSM, et al.
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol2012;
13: 100–110.
8.
ChatterjeeA.The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines2014;
13: 1279–1290.
9.
VelicerCZhuXVuocoloS, et al.
Prevalence and incidence of HPV genital infection in women. Sex Transm Dis2009;
36: 696–703.
10.
RodriguezACBurkRHerreroR, et al.
The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis2007;
34: 494–502.
11.
CastellsaguéXSchneiderAKaufmannAM, et al.
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol2009;
115: S15–S23.
12.
MunozNMendezFPossoH, et al.
Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis2004;
190: 2077–2087.
13.
FrancoELVillaLLSobrinhoJP, et al.
Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis1999;
180: 1415–1423.
14.
TrottierHFerreiraSThomannP, et al.
Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res2010;
70: 8569–8577.
15.
RositchAFBurkeAEViscidiRP, et al.
Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res2012;
72: 6183–6190.
16.
GravittPE.The known unknowns of HPV natural history. J Clin Invest2011;
121: 4593–4599.
17.
RodriguezACSchiffmanMHerreroR, et al.
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst2010;
102: 315–324.
18.
de SanjoseSDiazMCastellsagueX, et al.
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis2007;
7: 453–459.
19.
SmithJSMelendyARanaRK, et al.
Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health2008;
43: S5–25, S e1–41.
20.
HardyRJThompsonSG.Detecting and describing heterogeneity in meta-analysis. Stat Med1998;
17: 841–856.
21.
HigginsJPThompsonSGDeeksJJ, et al.
Measuring inconsistency in meta-analyses. BMJ2003;
327: 557–560.
22.
NyariTKalmarLNyariC, et al.
Human papillomavirus infection and cervical intraepithelial neoplasia in a cohort of low-risk women. Eur J Obstet Gynecol Reprod Biol2006;
126: 246–249.
23.
AhdiehLKleinRSBurkR, et al.
Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis2001;
184: 682–690.
24.
GoodmanMTShvetsovYBMcDuffieK, et al.
Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res2008;
68: 8813–8824.
25.
SilverbergMJAhdiehLMunozA, et al.
The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis2002;
29: 427–435.
26.
SyrjanenSShabalovaIPetrovichevN, et al.
Acquisition of high-risk human papillomavirus infections and pap smear abnormalities among women in the New Independent States of the Former Soviet Union. J Clin Microbiol2004;
42: 505–511.
27.
TrottierHMahmudSPradoJC, et al.
Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis2008;
197: 1436–1447.
28.
SunXWKuhnLEllerbrockTV, et al.
Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med1997;
337: 1343–1349.
29.
MendezFMunozNPossoH, et al.
Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis2005;
192: 1158–1165.
30.
RousseauMCPereiraJSPradoJC, et al.
Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis2001;
184: 1508–1517.
31.
TorneselloMLDuraturoMLGiorgi-RossiP, et al.
Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. J Gen Virol2008;
89: 1380–1389.
32.
SellorsJWKarwalajtysTLKaczorowskiJ, et al.
Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ2003;
168: 421–425.
33.
RousseauMCVillaLLCostaMC, et al.
Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis2003;
30: 581–587.
34.
CastlePESchiffmanMHerreroR, et al.
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis2005;
191: 1808–1816.
35.
ChaoAChangCJLaiCH, et al.
Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology–a population-based cohort study from Taiwan. Int J Cancer2009;
126: 191–198.
36.
RosaMIFachelJMRosaDD, et al.
Persistence and clearance of human papillomavirus infection: a prospective cohort study. Am J Obstet Gynecol2008;
199: 617.e1–7.
37.
SafaeianMKiddugavuMGravittPE, et al.
Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev2008;
17: 1300–1307.
38.
BanuraCSandinSvan DoornLJ, et al.
Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. Infect Agents Cancer2010;
5: 7.
39.
GiulianoARHarrisRSedjoRL, et al.
Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis2002;
186: 462–469.
40.
HoGYStudentsovYHallCB, et al.
Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis2002;
186: 737–742.
41.
RichardsonHKelsallGTellierP, et al.
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev2003;
12: 485–490.
42.
ThomasKKHughesJPKuypersJM, et al.
Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis2000;
182: 1097–1102.
43.
BrownDRFifeKHWheelerCM, et al.
Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine2004;
22: 2936–2942.
44.
InsingaRPDasbachEJElbashaEH, et al.
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agents Cancer2007;
2: 15.
45.
InsingaRPDasbachEJElbashaEH, et al.
Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev2007;
16: 709–715.
46.
InsingaRPPerezGWheelerCM, et al.
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev2010;
19: 1585–1594.
47.
KoutskyLAAultKAWheelerCM, et al.
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med2002;
347: 1645–1651.
48.
MoscickiABHillsNShiboskiS, et al.
Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA2001;
285: 2995–3002.
49.
CollinsSMazloomzadehSWinterH, et al.
High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG2002;
109: 96–98.
50.
OhJKJuYHFranceschiS, et al.
Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study. BMC Infect Dis2008;
8: 13.
51.
SycuroLKXiLFHughesJP, et al.
Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis2008;
198: 971–978.
52.
WinerRLHughesJPFengQ, et al.
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med2006;
354: 2645–2654.
53.
WinerRLLeeSKHughesJP, et al.
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American Journal of Epidemiology2003;
157: 218–226.
54.
WoodmanCBCollinsSRollasonTP, et al.
Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet2003;
361: 40–43.
55.
XiLFCarterJJGallowayDA, et al.
Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev2002;
11: 343–351.
56.
HoGYBiermanRBeardsleyL, et al.
Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med1998;
338: 423–428.
57.
HarperDMFrancoELWheelerC, et al.
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet2004;
364: 1757–1765.
58.
VeressGCsiky-MeszarosTKonyaJ, et al.
Follow-up of human papillomavirus (HPV) DNA and local anti-HPV antibodies in cytologically normal pregnant women. Med Microbiol Immunol1996;
185: 139–144.
59.
EvanderMEdlundKGustafssonA, et al.
Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis1995;
171: 1026–1030.
60.
KotloffKLWassermanSSRussK, et al.
Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis1998;
25: 243–250.
61.
NielsenAIftnerTMunkC, et al.
Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women. Sex Transm Dis2009;
36: 609–615.
62.
CuschieriKSWhitleyMJCubieHA.Human papillomavirus type specific DNA and RNA persistence–implications for cervical disease progression and monitoring. J Med Virol2004;
73: 65–70.
63.
LiawKLHildesheimABurkRD, et al.
A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis2001;
183: 8–15.
64.
ZouHSunYZhangG, et al.Positivity and incidence of human papillomavirus in women attending gynecological department of a major comprehensive hospital in Kunming, China 2012–2014. J Med Virol2016;
88: 703–711.
65.
DattaPBhatlaNPandeyRM, et al.
Type-specific incidence and persistence of HPV infection among young women: a prospective study in North India. Asian Pac J Cancer Prev2012;
13: 1019–1024.
66.
SchmeinkCEMassugerLFAGLenselinkCH, et al.
Prospective follow-up of 2,065 young unscreened women to study human papillomavirus incidence and clearance. Int J Cancer2013;
133: 172–181.
67.
LouvantoKRintalaMASyrjanenKJ, et al.
Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study. BMC Infect Dis2011;
11: 179.
68.
Watson-JonesDBaisleyKBrownJ, et al.
High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects. Sex Transm Infect2013;
89: 358–365.
69.
RibaldoneRBoldoriniRCapuanoA, et al.
Role of HPV testing in the follow-up of women treated for cervical dysplasia. Arch Gynecol Obstet2010;
282: 193–197.
70.
MarkowitzLEDunneEFSaraiyaM, et al.
Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2007;
56: 1–24.
71.
SaslowDCastlePECoxJT, et al.
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin2007;
57: 7–28.
72.
MuñozNManalastasRJrPitisuttithumP, et al.
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet373: 1949–1957.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
